The Cosentyx Drug Market is expected to experience steady growth, driven by the increasing prevalence of autoimmune and inflammatory diseases, rising demand for targeted biologic therapies, and ongoing developments in immunology-based treatments. Cosentyx (secukinumab) is a biologic medication developed by Novartis that belongs to the interleukin-17A (IL-17A) inhibitor class. It is used to...
